Physician profile

Matthew A Grossman

Gastroenterology (Internal Medicine) · Morristown, NJ

NPI 1063618908

$7,023.85

in general payments reported to CMS, 2019-2025

39 companies · $1,758 in 2025

The $1,758 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).

See the full distribution for Gastroenterology (Internal Medicine)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,320.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $1,358.31 2019-2025 Apollo Esg System, Nxt Tissue Helix Pro, Wallflex Duodenal
Abbvie INC. $954.69 2019-2025
Olympus America INC. $697.58 2019-2023 Visiglide, Evis Exera Lll Colonovideoscope
Medtronic, INC. $314.74 2021-2025 Nexpowder, Gi Genius
Gilead Sciences, INC. $313.48 2023-2025 Livdelzi
3-D Matrix, INC. $284.12 2025
Pfizer INC. $233.01 2023-2025
Covidien LP $228.16 2019
Genzyme Corporation $211.53 2025
Merit Medical Systems INC $198.75 2025 Esophyx
Amgen INC. $176.37 2025 Evenity, Uplizna
Apollo Endosurgery US INC $176.15 2021
Steris Corporation $164.17 2024-2025
Janssen Biotech, INC. $147.32 2023-2024 Stelara
Allergan, INC. $125.00 2020
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Davol INC. $121.50 2019
Phathom Pharmaceuticals, INC. $120.51 2025 Voquezna
Erbe USA INC $95.63 2024
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $89.56 2020-2024 Xifaxan
Endogastric Solutions, INC $86.20 2019
Evoke Pharma, INC. $84.18 2021-2022
Conmed Corporation $79.95 2023 Conmed Generators, Conmed Hemostasis, Conmed Biliary
Takeda Pharmaceuticals U.S.A., INC. $76.50 2022-2024 Entyvio, Eohilia
Qol Medical, LLC $75.14 2021-2024 Sucraid
Ferring Pharmaceuticals INC. $70.82 2023-2025 Rebyota
Ardelyx, INC. $58.55 2023-2025 Ibsrela
Capsovision, INC. $57.06 2024-2025 Capsocam Plus
Bayer Healthcare Pharmaceuticals INC. $56.31 2019-2022
Regeneron Healthcare Solutions, INC. $55.59 2024-2025 Dupixent
Nestle Healthcare Nutrition INC. $45.15 2022-2023
Galvanize Therapeutics, INC $39.52 2024 Aliya System
Aimmune Therapeutics, INC. $36.90 2024-2025 Vowst
Merck Sharp & Dohme LLC $36.82 2023 Dificid
Astrazeneca Pharmaceuticals LP $34.00 2024 Andexxa
Laborie Medical Technologies Corp. $31.79 2025
Vivus LLC $31.04 2022
Intercept Pharmaceuticals, INC. $22.78 2025
Madrigal Pharmaceuticals $19.25 2025 Rezdiffra
Organon LLC $15.72 2023 Hadlima

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew A Grossman

$7,023.85

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $1,758 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).

https://glasscript.com/doctor/48334/matthew-a-grossman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.